Skip to main content

Table 2 Participants, grouping according to Chronic Kidney Disease (CKD) stages, renal diagnoses, co-morbidity, demographic and laboratory data

From: Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment

  All patients (n = 535) CKD stage 2 – 3* GFR range 31–69 (n = 54) CKD stage 4** GFR range 15–29 (n = 87) CKD stage 5** GFR range 2–14 (n = 394) Controls* (n = 55)
Age, M (SD) 61 (15) 47 (11.2) 62 (15.7) 62 (14.4) 48 (10.6)
Females, n (%) 175 (33) 22 (41) 35 (40) 118 (30) 22 (40)
BMI, Md (IQR) 25 (22–28) 25 (22–28) 25 (23–28) 25 (22–28) 24 (22–27)
MAP, M (SD) 101 (15.4) 96 (12.8) 94 (13.4) 103 (5.6) 88 (10.4)
GFR, ml/min/1.73 m²§, M (SD) 15 (16) 60 (6.6) 19 (3.1) 8 (3) 99 (12)
Hb, g/L, M (SD) 115 (17) 136 (14.2) 122 (12.6) 111 (15.6) 142 (11.5)
p-Albumin,g/L, M (SD) 34 (5.5) 38 (3.6) 36 (4.4) 33 (5.6) 40 (2.8)
p-Phosphate, mmol/L, M (SD) 1.8 (0.6) 1.1 (0.2) 1.4 (0.3) 2.0 (0.6) 1.1 (0.2)
PTH, ng/L, Md (IQR) 160 (76–303) 46 (35–56) 146 (91–204) 201 (103–345) 43 (38–53)
CRP, mg/L, Md (IQR) 5 (4–18) 2.4 (1–4.4) 4 (1.6–8.9) 6 (5–23) 0.89 (0.5–2.3)
CRP = 5–10 mg/L, n (%) 182 (34) 5 (9) 17 (20) 160 (41) 2 (4)
CRP = >10 mg/L, n (%) 163 (30) 4 (7) 13 (15) 146 (37) 3 (5)
n, (%)      
Renal vascular disease 115 (22) 1 (2) 22 (25) 92 (23)  
Primary glomerulonephritis 95 (18) 18 (33) 12 (13) 65 (17)  
Familial, hereditary renal disease 58 (11) 12 (20) 6 (7) 40 (10)  
Secondary glomerular systemic diseasesa 46 (9) 2 (4) 5 (6) 39 (10)  
Other renal diagnose 101 (19) 13 (24) 20 (23) 68 (17)  
CVD history b 264 (49) 7 (13) 49 (56) 208 (53)  
Diabetes history c 158 (30) 11 (20) 40 (46) 107 (27)  
Other co-morbidityd 119 (22) 2 (4) 22 (25) 95 (24)  
  1. * GFR  = glomerular filtration rate in ml/min/1.73 m², examined by Iohexol-clearance.
  2. ** GFR estimated by MDRD.BMI = Body Mass Index, MAP = Mean Arterial Pressure, Hb = Hemoglobin. a Secondary glomerular systemic diseases except for diabetic nephropathy. b Cardiovascular disease (CVD) includes cardiac infarction, congestive heart failure, stroke/TIA, atherosclerosis/peripheral vascular disease. c Diabetic nephropathy or diabetes as co-morbidity. d Other co-morbidity includes malignancy, chronic respiratory disease, chronic liver disease and rheumatic disease.